Clinical Trial Update: IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating IDH2-mutant myeloid neoplasms after allogeneic stem cell transplantation. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED